Precision for Medicine and Agena Bioscience announce strategic partnership
The strategic partnership combines cutting-edge molecular profiling technology with unparalleled biospecimen and tissue profiling services
26 Nov 2024
Precision for Medicine, a leading next-generation provider of drug development research and services, has announced a strategic partnership with Agena Bioscience that helps bridge critical gaps in detecting mutations not identified by next-generation sequencing (NGS) alone. Precision for Medicine and Agena Bioscience presented findings on profiling challenging lung tumor samples at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, held November 19-23, 2024.
Dr. Darren Davis, Senior Vice President at Precision for Medicine, revealed the results of the joint study on the Agena iPLEX® HS Lung Panel on the MassARRAY® System. The study showed that the Agena iPLEX HS Lung Panel on the MassARRAY System identified mutations in 40% of formalin-fixed paraffin-embedded (FFPE) lung tumor samples that had previously failed quality metrics on leading NGS platforms. Among these findings were actionable mutations in five clinically relevant genes: KRAS, EGFR, BRAF, ERBB2 and PIK3CA.
Additionally, the MassARRAY System demonstrated a significantly lower failure rate of 2% compared to the 22% observed with NGS platforms, offering significant advantages in both research and clinical workflows.
The results showed remarkable reliability, achieving 100% positive predictive value (PPV) and 99.7% negative predictive value (NPV) through ddPCR validation, providing an extra layer of confidence compared to typical sequencing results from other service providers. These findings represent a significant advancement in diagnostics and offer a robust solution for identifying actionable mutations in challenging lung cancer cases.
With comprehensive sequencing already conducted across 23 oncology indications, Precision for Medicine's offering promises to provide significant cost savings with high-quality, annotated samples ready for immediate use. When paired with the MassARRAY system that generates actionable data within 1-2 days, compared to the 10–15-day typical lead time with NGS, this capability accelerates and streamlines client timelines.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>